Rasha Aljelaify

Rasha Aljelaify

Auto-generated profile, based on publicly available information

Rasha Aljelaify

Genomics Research Department, Saudi Human Genome Project, King Fahad Medical City and King Abdulaziz City for Science and Technology, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2015 in Cell Reports
Verified
Journal Article
Open access
AAAnas M. Alazami
Anas M. Alazami
NPNisha Patel
Nisha Patel
HSHanan E. Shamseldin
Hanan E. Shamseldin
SAShamsa Anazi
Shamsa Anazi
MAMohammed S. Al-Dosari
Mohammed S. Al-Dosari
FAFowzan S. Alkuraya
Fowzan S. Alkuraya
Our knowledge of disease genes in neurological disorders is incomplete. With the aim of closing this gap, we performed whole-exome sequencing on 143 multiplex consanguineous families in whom known disease genes had been excluded by autozygosity mapping and candidate gene analysis. This prescreening step led to the identification of 69 recessive genes not previously associated with disease, of which 33 are here described (SPDL1, TUBA3E, INO80, NID1, TSEN15, DMBX1, CLHC1, C12orf4, WDR93, ST7, MATN4, SEC24D, PCDHB4, PTPN23, TAF6, TBCK, FAM177A1, KIAA1109, MTSS1L, XIRP1, KCTD3, CHAF1B, ARV1, ISCA2, PTRH2, GEMIN4, MYOCD, PDPR, DPH1, NUP107, TMEM92, EPB41L4A, and FAM120AOS). We also encountered instances in which the phenotype departed significantly from the established clinical presentation of a known disease gene. Overall, a likely causal mutation was identified in >73% of our cases. This study contributes to the global effort toward a full compendium of disease genes affecting brain function.

6 August 2013 in Nature Communications
Verified
Journal Article
Open access
PDF file
IAIbrahim S. Al-Mssallem
Ibrahim S. Al-Mssallem
SHSongnian Hu
Songnian Hu
XZXiaowei Zhang
Xiaowei Zhang
QLQiang Lin
Qiang Lin
WLWanfei Liu
Wanfei Liu
JYJun Yu
Jun Yu
Date palm (Phoenix dactylifera L.) is a cultivated woody plant species with agricultural and economic importance. Here we report a genome assembly for an elite variety (Khalas), which is 605.4 Mb in size and covers >90% of the genome (~671 Mb) and >96% of its genes (~41,660 genes). Genomic sequence analysis demonstrates that P. dactylifera experienced a clear genome-wide duplication after either ancient whole genome duplications or massive segmental duplications. Genetic diversity analysis indicates that its stress resistance and sugar metabolism-related genes tend to be enriched in the chromosomal regions where the density of single-nucleotide polymorphisms is relatively low. Using transcriptomic data, we also illustrate the date palm’s unique sugar metabolism that underlies fruit development and ripening. Our large-scale genomic and transcriptomic data pave the way for further genomic studies not only on P. dactylifera but also other Arecaceae plants.

13 August 2018 in The Oncologist
Verified
Journal Article
Closed access
PDF file
MAMusa AlHarbi
Musa AlHarbi
NMNahla Ali Mobark
Nahla Ali Mobark
LALatifa AlMubarak
Latifa AlMubarak
RARasha Aljelaify
Rasha Aljelaify
MAMariam AlSaeed
Mariam AlSaeed
MAMalak Abedalthagafi
Malak Abedalthagafi
Primary brain tumors are a leading cause of cancer‐related morbidity and mortality in children. Glioblastoma (GBM) is a high‐grade astrocytoma that occurs in both children and adults and is associated with a poor prognosis. Despite extensive study in recent years, the clinical management of these tumors has remained largely unchanged, consisting of surgical resection, conventional chemotherapy, and radiotherapy. Although the etiology and genomic drivers in GBM are diverse, constitutional mismatch repair‐deficiency (CMMRD) syndrome is a rare, recessively inherited disease with a predisposition to gliomagenesis. CMMRD results from biallelic mutations in one of the mismatch repair genes including mutL homolog 1 (MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6), and post‐meiotic segregation increased 2 (PMS2). In this report, we present the case of a 5‐year‐old female with GBM and CMMRD due to an MSH6 homozygous c.1883G>A mutation, who continues to experience an exceptional and durable response (9 months) to the immune checkpoint inhibitor (ICPI) nivolumab. Our patient presented with acute neurologic decline and increased intracranial pressure. Neuroimaging studies revealed a large left frontoparietal mass requiring neurosurgical decompression and resection. Histopathologic analyses resulted in a diagnosis of de novo GBM that was BRAF wild type and negative for programmed death‐ligand 1 protein expression. She received standard‐of‐care treatment with surgery, radiation therapy, and temozolomide; however, the tumor recurred 3 months after the initial diagnosis. Molecular analyses of tumor and blood tissues revealed an MSH6 homozygous c.1883G>A mutation consistent with CMMRD. Given her CMMRD status, she was treated with nivolumab (3 mg/kg doses every 2 weeks for 36 weeks) and showed a 60% reduction in tumor size, improved clinical symptoms, and an ongoing durable response lasting 10 months to date. Our study highlights a durable response to the ICPI nivolumab in a pediatric patient with recurrent/refractory CMMRD‐associated GBM. We show that incorporating genomic and/or molecular testing for CMMRD into routine pediatric oncology clinical care can identify a subset of patients likely to benefit from ICPI. Key Points. Constitutional mismatch repair‐deficiency (CMMRD) syndrome, alternatively known as biallelic mismatch repair deficiency syndrome, occurs in subset of pediatric cancer patients, including those with primary brain tumors. Patients from Arab and other developing countries are predicted to have higher incidence of CMMRD due to high prevalence of consanguinity. Integration of molecular and/or genomic testing into routine clinical care for pediatric cancer patients is important to identify patients with CMMRD syndrome. Patient with CMMRD‐associated cancers may show increased responsiveness to immune checkpoint inhibitors. To the authors' knowledge, this is the first report in the Arab world of a durable response to immune checkpoint inhibitors in a pediatric glioblastoma patient.

20 March 2020 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
MAMusa Alharbi
Musa Alharbi
NMNahla Mobark
Nahla Mobark
YBYara Bashawri
Yara Bashawri
LSLeen Abu Safieh
Leen Abu Safieh
AAAlbandary Alowayn
Albandary Alowayn
MAMalak Abedalthagafi
Malak Abedalthagafi
Medulloblastoma (MB) is the most common childhood malignant brain tumor and is a leading cause of cancer-related death in children. DNA methylation profiling has rapidly advanced our understanding of MB pathogenesis at the molecular level, but assessments in Saudi Arabian (SA)-MB cases are sparse. MBs can be sub-grouped according to methylation patterns from FPPE samples into Wingless (WNT-MB), Sonic Hedgehog (SHH-MB), Group 3 (G3), and Group 4 (G4) tumors. The WNT-MB and SHH-MB subgroups are characterized by gain-of function mutations that activate oncogenic cell signaling, whilst G3/G4 tumors show recurrent chromosomal alterations. Given that each subgroup has distinct clinical outcomes, the ability to subgroup SA-FPPE samples holds significant prognostic and therapeutic value. Here, we performed the first assessment of MB-DNA methylation patterns in an SA cohort using archival biopsy material (FPPE n = 49). Of the 41 materials available for methylation assessments, 39 could be classified into the major DNA methylation subgroups (SHH, WNT, G3, and G4). Furthermore, methylation analysis was able to reclassify tumors that could not be sub-grouped through next-generation sequencing, highlighting its superior accuracy for MB molecular classifications. Independent assessments demonstrated known clinical relationships of the subgroups, exemplified by the high survival rates observed for WNT tumors. Surprisingly, the G4 subgroup did not conform to previously identified phenotypes, with a high prevalence in females, high metastatic rates, and a large number of tumor-associated deaths. Taking our results together, we demonstrate that DNA methylation profiling enables the robust sub-classification of four disease sub-groups in archival FFPE biopsy material from SA-MB patients. Moreover, we show that the incorporation of DNA methylation biomarkers can significantly improve current disease-risk stratification schemes, particularly concerning the identification of aggressive G4 tumors. These findings have important implications for future clinical disease management in MB cases across the Arab world.

4 April 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NGNatalie J. Groves
Natalie J. Groves
DBDanaKai Bradford
DanaKai Bradford
RSRobert K. P. Sullivan
Robert K. P. Sullivan
KCKyna-Anne Conn
Kyna-Anne Conn
RARasha Fahad Aljelaify
Rasha Fahad Aljelaify
TBThomas H. J. Burne
Thomas H. J. Burne
Epidemiological studies have shown that up to one third of adults have insufficient levels of vitamin D and there is an association between low vitamin D concentrations and adverse brain outcomes, such as depression. Vitamin D has been shown to be involved in processes associated with neurogenesis during development. Therefore, the aim of this study was to test the hypothesis that adult vitamin D (AVD) deficiency in BALB/c mice was associated with (a) adult hippocampal neurogenesis at baseline, b) following 6 weeks of voluntary wheel running and (c) a depressive-like phenotype on the forced swim test (FST), which may be linked to alterations in hippocampal neurogenesis. We assessed proliferation and survival of adult born hippocampal neurons by counting the number of cells positive for Ki67 and doublecortin (DCX), and incorporation of 5-Bromo-2’-Deoxyuridine (BrdU) within newly born mature neurons using immunohistochemistry. There were no significant effects of diet on number of Ki67+, DCX+ or BrdU+ cells in the dentate gyrus. All mice showed significantly increased number of Ki67+ cells and BrdU incorporation, and decreased immobility time in the FST, after voluntary wheel running. A significant correlation was found in control mice between immobility time in the FST and level of hippocampal neurogenesis, however, no such correlation was found for AVD-deficient mice. We conclude that AVD deficiency was not associated with impaired proliferation or survival of adult born neurons in BALB/c mice and that the impact on rodent behaviour may not be due to altered neurogenesis per se, but to altered function of new hippocampal neurons or processes independent of adult neurogenesis.

17 September 2019 in Oncotarget
Verified
Journal Article
Open access
PDF file
AAAysha AlSahlawi
Aysha AlSahlawi
RARasha Aljelaify
Rasha Aljelaify
AMAmna Magrashi
Amna Magrashi
MAMariam AlSaeed
Mariam AlSaeed
AAAmal Almutairi
Amal Almutairi
MAMalak Abedalthagafi
Malak Abedalthagafi
Oncotarget | https://doi.org/10.18632/oncotarget.27178 Aysha AlSahlawi, Rasha Aljelaify, Amna Magrashi, Mariam AlSaeed, Amal Almutairi, Fatimah Alqubaishi, Abdulellah Alturkistani, Abdullah AlObaid, Mohamed...